Awakn Life Sciences Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AWKNF research report →
Price Chart
About the company
Awakn Life Sciences Corp., a biotechnology firm, focuses on pioneering, advancing, implementing, and distributing psychedelic therapies to combat addiction and various other mental health conditions. Operating across the United Kingdom and Europe, the company maintains its corporate headquarters in Toronto, Canada.
- CEO
- Anthony Tennyson
- IPO
- 2021
- Employees
- 6
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on AWKNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.71M
- P/E
- -0.28
- PEG
- -0.00
- P/S
- 2.58
- P/B
- 2.97
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
- Gross Margin
- -103.97%
- Op Margin
- -614.85%
- Net Margin
- -611.40%
- ROE
- -429.34%
- ROIC
- -331.42%
Latest fiscal year · YoY change
- Revenue
- $87.37K-94.2%
- Gross Profit
- $87.37K-90.2%
- Op Income
- $-3,926,493
- Net Income
- $-5,102,704+44.2%
- EPS
- $-0.13+63.9%
- OCF Growth
- +67.7%
- FCF Growth
- +68.1%
- 52W High
- $0.13
- 52W Low
- $0.05
- 50D MA
- $0.07
- 200D MA
- $0.07
- Beta
- 2.60
- RSI (14)
- 38
- Avg Volume
- 8.84K
No earnings-call transcripts are available for AWKNF yet.
- Free Float
- 87.6%
- Shares Outstanding
- 41.66M
- Float Shares
- 36.50M
Our AWKNF coverage
Recent articles, reports, and earnings notes.
No research on AWKNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AWKNF report →Solvonis Therapeutics completes acquisition of Awakn Life Sciences
proactiveinvestors.co.uk · May 28
CSE Bulletin: Delist - Awakn Life Sciences Corp. (AWKN)
newsfilecorp.com · May 27
Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc
newsfilecorp.com · May 27
Awakn Life Sciences Announces Shareholder Approval of Arrangement
newsfilecorp.com · Apr 23
Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
newsfilecorp.com · Apr 11
Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc
newsfilecorp.com · Feb 27
Solvonis Therapeutics lays out roadmap for Awakn Life Sciences acquisition
proactiveinvestors.co.uk · Feb 24
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
newsfilecorp.com · Jan 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.